IMS Health
Global oncology market to reach $150 billion by 2020, says IMS Health
June 2, 2016Research and Development IMS Health, annual global growth, cancer drugs, oncology
Global sales of oncology drugs rose to $107 billion in 2015, according to a new IMS Health report, with growth …
Quintiles to merge with IMS Health
May 3, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …
US annual spending on drugs rose 12.2% in 2015 – IMS
April 15, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending
The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
Global drug spending will rise 30% by 2020, to $1.4 trillion
November 18, 2015Research and Development IMS Health, OTC, drug spending, emerging markets, generics, prescribing
Global spending on drugs will increase 30% to $1.4 trillion by 2020, as more patients get access to treatments and …
Worldwide cancer spending tops $100 billion
May 5, 2015Research and Development, Sales and Marketing Cancer, IMS Health, keytruda, oncology
Over $100 billion was spent on cancer medicines across the world last year as a new generation of drugs begins …
IMS Health appoints general manager
March 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IMS Health, sheppard
Technology services firm IMS Health has named Tim Sheppard as the new general manager for its UK and Ireland business. Sheppard …
HGS founders join IMS Health team
October 23, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HGS, IMS Health, mcfarlane
Healthcare services firm IMS Health has appointed HGS Europe founders Graeme McFarlane and Angela McFarlane (pictured) to its UK team.
Fitch to pharma: don’t expect 2012 to be a bumper year
July 31, 2012Sales and Marketing 2012, FDA approvals, Fitch, IMS Health, NMEs, ratings
The Fitch ratings agency has published pessimistic projections for pharma, saying that it should not expect as many US drug …
Generic approval for Shire’s hyperactivity drug
June 26, 2012Sales and Marketing ADHD, Adderall XR, FDA, IMS Health, Impax, Shire, Teva
US regulators have delivered a blow to Shire by allowing Actavis Group to produce a generic version of its hyperactivity …
AstraZeneca does data deal
January 13, 2012Sales and Marketing AstraZeneca, IMS Health, data
AstraZeneca has signed a deal with an information company in a bid to improve the data it has on how …
Generics push US drug growth to $307bn
April 20, 2011IMS, IMS Health, drug spending, healthcare spending
Generics replaced branded drugs as the main growth drivers for the US pharmaceutical market in 2010. The market saw just …
Pharma sector growth to improve in 2011
November 19, 2010Sales and Marketing 2011, IMS, IMS Health, forecast, growth, pharma
2011 should be a better year for pharma as emerging markets and recovering economies will help growth, say analysts at …
Pfizer extends portfolio with Brazilian generics deal
October 21, 2010Brazil, IMS Health, Pfizer, em, emerging pharma marketings
Pfizer is partnering with leading Brazilian generics firm Laboratorio Teuto Brasileiro to develop and commercialise a number of generic products …
Latest content
FibroFind appoints Lee Borthwick as CEO
